Public Company Edition: Actuate Therapeutics grossed $22.4m in its first-time offering, while already-public companies recently tapped a variety of sources for funding. Arrowhead negotiated a credit facility for up to $500m and ANI sold $275m worth of notes, among other financings.

Plus transactions involving ANI/Alimera, Gilead/ashibio, Sanofi/Belharra and more.

Strong sales growth and licensing activity in 2023 helped multiple Chinese biotechs to a solid profit performance, some moving into the black for the first time.

Plus deals involving Biocytogen, Neurocrine and Ona, Aeterna Zentaris/Ceapro, Teva/Biolojic Design, Pathos AI/Rain Oncology, Inhibitor Therapeutics/Johns Hopkins and more.